---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-065073"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:41:12.008326+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports positive Phase 2 results for RZ402 in DME; CST reduced up to ~50 microns

## Summary
- Phase 2 study of 94 DME patients met primary endpoints: CST reduction (p=0.02) and good safety profile.
- CST improvement up to ~50 microns; 200 mg dose showed largest response; sub-analysis at CST ≥400 showed ~75 micron improvement.
- RZ402 safe and well-tolerated; AEs mild and comparable to placebo; no ocular adverse effects typical of intravitreal injections.
- No significant BCVA improvement, consistent with study duration; five 200 mg patients (20%) had 1-step DRSS improvement.
- Target concentrations exceeded at all three doses (50, 200, 400 mg) supporting once-daily oral dosing.

## SEC filing metadata
- accession: 0001104659-24-065073
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924065073/0001104659-24-065073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924065073/tm2415552d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-065073
- JSON: https://secwatch.observer/filing/0001104659-24-065073.json
- Plain text: https://secwatch.observer/filing/0001104659-24-065073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.